CanSino Biologics Inc. (HKG:6185)

Hong Kong · Delayed Price · Currency is HKD

26.70

-0.46 (-1.69%)

Nov 11, 2026, 4:08 PM HKT

CanSino Biologics Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,258	1,068	846.34	357.08	1,035	4,300
Revenue Growth	29.41%	26.18%	137.01%	-65.49%	-75.94%	17174.82%
Gross Profit	931.62	804.23	583.58	-443.75	-183.71	3,002
Operating Income	-67.65	-87.76	-348.78	-1,723	-1,499	1,784
Net Income	29.72	27.87	-378.88	-1,483	-909.43	1,914
Earnings Per Share	0.12	0.11	-1.53	-6.01	-3.68	7.74
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
People's Republic of China (PRC)	1,012
Overseas	47.75
Total	1,059

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	1,775	2,644	3,204	4,130	5,947	7,783
Total Debt	929.56	1,289	2,013	2,700	2,701	1,375
Net Cash (Debt)	845.94	1,355	1,191	1,430	3,246	6,408
Net Cash Growth	-38.06%	13.79%	-16.70%	-55.95%	-49.34%	28.90%
Net Cash Per Share	3.42	5.35	4.81	5.80	13.14	25.91

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	33.63	90.98	-167.29	-908.23	-1,852	2,050
Capital Expenditures	-158.99	-243.9	-457.64	-610.47	-1,075	-1,203
Free Cash Flow	-125.36	-152.92	-624.93	-1,519	-2,927	846.86
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	74.08%	75.31%	68.95%	-124.27%	-17.76%	69.82%
Operating Margin	-5.38%	-8.22%	-41.21%	-482.38%	-144.89%	41.49%
Pretax Margin	2.88%	2.04%	-45.04%	-554.35%	-114.44%	45.04%
Profit Margin	2.36%	2.61%	-44.77%	-415.23%	-87.90%	44.52%
FCF Margin	-9.97%	-14.32%	-73.84%	-425.31%	-282.87%	19.70%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	190.00	407.26	-	-	-	28.13
Forward PE	21.43	45.28	39.62	39.62	268.75	11.16
P/FCF Ratio	-	-	-	-	-	63.60
PS Ratio	9.39	10.63	12.89	31.81	23.68	12.53